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ABSTRACT 
Objectives: To describe the incidence of renal dysfunction, hypokalaemia and 
hypomagnesaemia in AIDS patients with cryptococcal meningitis and on amphotericin B 
treatment. Secondary objective was to determine all-cause mortality in the same group. 
Design: Prospective, observational study. 
Setting: Kenyatta National Hospital (KNH), Nairobi, Kenya. 
Subjects: Seventy consecutive patients with AIDS and cryptococcal meningitis on 
amphotericin B. 
Results: About 58.6% of the patients had at least 100% rise in the creatinine level. 
Thirty eight point six per cent of patients experienced a rise in serum creatinine of at 
least 50%. Ninty three per cent of the patients developed hypokalaemia and 80% had 
hypomagnesaemia at trough magnesium level. Only 54.3% of patients completed the 
intended 14-day treatment. Thirty point five per cent of patients died within the two 
week follow-up period. 
Conclussion: The incidences of amphotericin B associated nephrotoxicity, hypokalemia 
and hypomagnesaemia were high in this studied population. 
INTRODUCTION 
Sub-Saharan Africa accounts for about 68% of the 
reported 33.2 million HIV/AIDS cases in 2007 (1). 
Kenya contributes its share to this pandemic with 
an estimated 7% prevalence rate (2). Cryptococcal 
meningitis is a common opportunistic infection 
in AIDS patients, particularly in Southeast Asia 
and Africa (3, 4) and it is associated with high 
mortality (5).
 Amphotericin B is the drug of choice for 
the treatment of severe systemic fungal illnesses, 
including cryptococcal meningitis. However, the 
main deterrent for its use is nephrotoxicity. Impaired 
renal function is a common complication of using 
amphotericin B, occurring in 5 to 80% of cases (6-
10). Renal dysfunction includes: renal insufficiency, 
urinary potassium wasting and hypokalaemia., 
urinary magnesium wasting and hypomagnesaemia., 
metabolic acidosis due to type 1 (or distal) renal 
tubular acidosis, and polyuria due to nephrogenic 
diabetes insipidus (6-8,11). 
 Pharmaco-economic consideration leaves 
amphotericin B deoxycholate as the drug of choice 
for treatment of cryptococcal meningitis in Kenya 
and other developing nations. Nephrotoxicity of 
amphotericin B adversely affects mortality, length 
of hospital stay and cost of  treatment (12-14). 
 Nephrotoxicity associated with amphotericin B 
is usually reversible with discontinuation of therapy 
but can recur if treatment is reinstituted (15, 16). 
 There is no universal consensus on monitoring 
of amphotericin B therapy but most commonly 
used tests include serum urea and serum creatinine 
concentration, complete blood count (CBC), serum 
magnesium and potassium levels. 
The main objective of this study was to determine 
the incidence of nephrotoxicity through serial 
creatinine, creatinine clearance, potassium and 
magnesium measurements. These were correlated 
with demographic variables. The secondary objectives 
were to determine the two week all cause mortality 
and the proportion of patients failing to complete the 
intended 14-day therapy. 
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MATERIALS AND METHODS 
Between July and October 2007, 84 patients with AIDS 
aged 18 years and above, with cryptococcal meningitis 
diagnosed by India ink staining or cryptococcal 
antigen (CRAG) test on CSF., were recruited into the 
study. The exclusion criteria are listed in Table 1.
Table 1
Study exclusion criteria 
Any critically ill patient who is unlikely to 
survive at least three days of the study. 
Any patient with contraindication to 
amphotericin B 
Any patient on nephrotoxin known to exacerbate 
amphotericin B renal toxicity including- 
acyclovir, aminoglycosides, carboplatin, cisplatin, 
cyclosporin, foscarnet, frusemide, non-steroidal 
anti-inflammatory agents, radio-contrast 
dye, rifampicin, intravenous co-trimoxazole, 
tacrolimus and vancomycin. 
Any patient with uncorrected hypokalaemia at 
initiation of amphotericin B therapy. 
Patients were recruited from the medical wards 
daily and relevant medical history and physical 
examination performed by the principal investigator. 
The patient’s general condition was assessed, 
including the presence of dehydration which was 
noted and the primary clinician informed on the 
need for re-hydration.The overall severity of illness 
was assessed using the Karnofsky performance 
status scale. Amphotericin B was administered at a 
dose of 0.7mg/kg infused in 500ml 5% dextrose over 
two to four hours. Potassium was supplemented 
intravenously as potassium chloride infusion 
(dose decided by primary clinician). Patients were 
preloaded with at least a litre of normal saline before 
each dose of amphotericin B. 
 Urinalysis (dip-stick method) was done 
before and at the end or stoppage of the therapy. 
If negative for protein by dipstick, the sample at 
end of therapy was assayed for micro-albuminuria. 
The CD4 count was measured before initiating the 
therapy. The serum potassium was measured daily 
for six days then on alternate days thereafter. Serum 
magnesium and Creatinine were measured at the 
start of amphotericin B therapy and on days 3, 6, 10 
and 14 of therapy. Creatinine clearance (Ccr) estimate 
was calculated using Cockcroft and Gault formula at 
the start of therapy and after each serum creatinine 
measurement. The baseline creatinine clearance at the 
start of therapy and the lowest creatinine clearance 
which corresponded with peak creatinine were noted. 
These two values were analysed to determine any 
deterioration of renal function. 
 Changes in creatinine level were also assessed 
as per the criteria used in other studies (17,18). 
Definition 0:  Increase in serum creatinine of <46 
µmol/L from baseline 
Definition 1:  Increase in serum creatinine of 46-
92µmol/L from baseline 
Definition 2:  50% increase of serum creatinine over 
the baseline 
Definition 3:  Increase in serum creatinine of 93-
230µmol/L from baseline 
Definition 4:  Doubling in serum creatinine over the 
baseline 
Definition 5:  Increase in creatinine to >230 µmol/L 
Nephrotoxicity that met any of definitions 1-4 was 
considered mild to moderate, whereas definition 5 
was considered severe. Peak creatinine level was 
defined as the maximum creatinine value measured 
for each patient during the study evaluation period. 
This is the value which was used in analysis. Change 
in creatinine was the difference between the peak and 
baseline creatinine. 
 Hypokalaemia was defined as serum potassium 
of less than 3.5 mmol/litre, with values of 3-3.49 
mmol/litre classified as significant and less than 
3 mmol/litre as severe hypokalaemia. Trough 
potassium was the lowest potassium value measured 
during the study period for each patient and this is 
the value which was analysed. Hypomagnesaemia 
was defined as serum magnesium less than 0.7 
mmol/L and the baseline and trough value of 
the measured serum magnesium were the values 
analysed. 
Data analysis: Data were cleaned and coded before 
input into SPSS version 12.0.1. The incidence of 
significant rise in creatinine, hypokalaemia and 
hypomagnesaemia were calculated. The data were 
analysed using several different statistical tests to 
determine univariate associations namely: Pearson 
correlation, Wilcoxon signed rank test and Fisher’s 
exact test. The results were considered statistically 
significant at P < 0.05. Multiple-regression was applied 
to determine correlation between variables. 
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RESULTS 
Baseline characteristics of the patients studied are shown in Table 2. 
Table 2
Baseline characteristics of study population 
Variable  Frequency  (%)  
Gender  
  Male  39  55.7  
  Female  31  44.3 
Age group (years)  
  <20  2  2.9  
  21-30  20  28.6  
  31-40  23  31.9  
  41-50  14  20.0  
  >50  11  15.7  
  Mean age 37.1 ±11.13 (range 18-62)  
Basis of diagnosis cryptococcal meningitis  
  Positive CSF India ink  60  85.7  
  Positive CSF CRAG  6  8.6  
  Both India ink and CSF CRAG  4  5.7  
Severity of illness KS Score  
  40%  1  1.4  
  60%  2  2.9  
  70%  6  8.6  
  80%  11  15.7  
  90%  19  27.1  
  100%  31  44.3  
CD4 Count (cell/microlitre)  
  <50  47  67.1  
  50-100  16  22.9  
  >100  7  10.0  
Mean 53.6 cells/microl       
The results of the mean baseline and mean peak 
creatinine values and corresponding estimated 
creatinine clearance are tabulated in Table 3. Similar 
results for baseline and trough serum potassium 
and magnesium levels are also shown. All these 
parameters showed significant changes. 
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Table 3
Baseline and peak creatinine and baseline and trough potassium and magnesium 
 Mean baseline  Mean peak  Mean trough  Change  Significance 
     of  change  
Creatinine (µmol/l)  75.6* (70.5-80.7)  176.2 (158.7-193.8)    100.6  0.000 P<0.01  
Creatinine clearance  93.6 (85.8-101.5)  43.6 (38.8-48.4) 50  0.000 P<0.01  
(ml/min/l.73m2)           
Potassium (mmol/l)  4 (3.9-4.1)   2.8 (1.9-3.7)   1.2  0.000 P<0.01 
Magnesium (mmol/l)  0.9 (0.85-0.95)   0.55 (0.50-0.59) 0.36  0.000 P<0.01 
        
*Data presented as mean (95% Confidence Interval) 
The severity of nephrotoxicity is shown in Table 4.
Table 4
Classification of nephrotoxicity 
Absolute values     Percentage rise in creatinine   
Nil (def: 0)  1.5 (21.4%)    Nil (<50%)  24.3%   
Mild to moderate (def: 1-4) 51 (72.9%)  50% rise serum creatinine (def 2) 27.1%   
Severe   4 (5.7%)  100% rise serum creatinine (def 4)  58.6%   
def = definition
definition of nephrotoxicity is as outlined under materials and methods        
 
Classification by severity of hypokalaemia revealed 
that 7.1% of study patients had no hypokalaemia, 21.7% 
had significant (3.0 -3.49 mmol/L) hypokalaemia and 
65% had severe (less than 3mmol/L) hypokalaemia. 
Correlation of nephrotoxicity, hypokalaemia and 
hypomagnesaemia with socio-demographic and 
other variables are as tabulated in Table 5. 
Table 5
Correlation of nephrotoxicity, hypokalaemia and hypomagnesaemia with different variables 
Variable Rise in creatinine Fall in creatinine  Fall in   Fall in magnesium 
 level clearance potassium level
 
Baseline value  0.000***  0.000***  0.000***  0.000***   
KS Score (%) 0.561 0.069   0.368   0.760   
CD4 count   0.319  0.323  0.363  0.927   
Age group (<35  0.005**  0.006**  0.111  0.857   
and >35 years) 
Gender/Sex   0.127   0.232  0.257  0.317   
*** P < 0.001, ** P < 0.01. All comparisons by Wilcoxon-rank test except by Fisher’s exact test
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DISCUSSION 
There are two previously used criteria for amphotericin 
B nephrotoxicity using serum Creatinine levels 
namely;  doubling of creatinine over baseline and a 
50% increase in the baseline serum creatinine and 
achieving a peak of 2.0 mg/dl (177 µmol/L). 
Using the first definition , the incidence of 
nephrotoxicity in our study was 58.6%. This is 
higher than in previous studies, where 24-53% of the 
patients studied had nephrotoxicity (9,19-26). Using 
the second definition, our incidence of nephrotoxicity 
was 38.6%. This was also higher compared with 
previous studies where the incidence was 8.5-30% 
(12,27-30).  The incidence of nephrotoxicity, using any 
of the two criteria was higher in our study compared 
to most other studies and this finding is contrary to 
the expectation as factors which enhance toxicity like 
concomitant nephrotoxic drugs and dehydration were 
addressed in the exclusion criteria of our study and 
not in some of the other studies. Our study also used 
lower daily and cumulative doses than most of the 
other studies. A plausible explanation is that AIDS 
predisposes the patient to greater nephrotoxicity than 
other underlying conditions (e.g. malignancy) in the 
other studies. This explanation was also favoured 
by Bates et al (10) who scored HIV highly as per 
the Charlson score used to assess severity of illness 
in their study. Charlson score correlated well with 
nephrotoxicity. 
 Another possibility is that the toxicity is higher 
in the African race which was our study population 
compared with the Caucasians (majority in the other 
studies). It is worth noting that there were differences 
in design (some retrospective) and study population 
between our study and these other previous 
studies. 
 Concerning the classification of severity of 
nephrotoxicity, the patients in this study had more 
severe toxicity than in the study by Luber et al (18). 
The incidence of hypokalaemia (92.8%) in our study 
was much higher than in the previous studies where the 
incidence ranged between 0 to 83% with most studies 
showing an incidence below 20% (17,31-36).
 This is also contrary to expectation considering 
that all the patients had potassium supplementation, 
the supplemented amount being decided upon by 
the primary clinician. A possible explanation is that 
the supplementation of potassium was inadequate. 
A second plausible explanation is that the potassium 
wasting in AIDS patients with cryptococcal meningitis 
may be more severe than in other populations studied 
may be due to more severe tubular dysfunction in 
AIDS.  
 The study designs and study populations in these 
other studies were also different from our study. 
 When further analysed by severity, not only 
did more of our patients develop hypokalaemia but 
larger proportion (68% vs. 30%) developed severe 
hypokalaemia compared with the findings of Bates 
et al (10). This may be again due to inadequate 
replacement of potassium or more tubular toxicity 
in our study population. 
Though not an objective of the study, the finding 
of baseline hypomagnesaemia in 20% of the study 
population is interesting and should probably 
be explored in future studies. The prevalence of 
hypomagnesaemia (80%) was comparable if not 
higher than in study by Bates et al (10) where the 
prevalence was 72%. Whang et al (37) suggested 
that it is difficult to correct hypokalaemia unless one 
also corrects the hypomagnesaemia. Our study did 
not correlate hypomagnesaemia with hypokalaemia 
but our finding of high incidence of hypokalaemia 
may be partly due to the high prevalence of 
hypomagnesaemia. 
The peak creatinine showed correlation with baseline 
creatinine and similarly baseline creatinine clearance 
showed a correlation with creatinine clearance. There 
was also a significant correlation between peak 
creatinine (and creatinine clearance derived from 
the same) and age. This is similar to the findings in 
the study by Bates et al (10) Therefore, age seems to 
be a consistent predictor of amphotericin B induced 
nephrotoxicity. 
 The other variables (gender, CD4 count, severity 
of illness) did not show a statistically significant 
correlation with the peak creatinine. This contrasts 
with the findings of Bates et al (10) where there was 
demonstrable significant correlation between severity 
of illness and nephrotoxicity. A likely explanation 
for the lack of correlation with severity of illness is 
that the Karnofsky score as a marker of severity of 
illness may not correlate with nephrotoxicity unlike 
the Charlson score. It is imperative to note that AIDS 
has a high score in the Charlson score and thus the 
whole of our study population would have a high 
score for severity of illness and cannot be stratified 
by the Charlson score. It is also possible that this 
study had fewer subjects and was not powered to 
show such correlation especially considering that the 
results showed a trend despite not being statistically 
significant. 
In conclusion, there is a high incidence of 
nephrotoxicity, hypokalaemia and hypomagnesaemia 
in AIDS patients treated for cryptococcal meningitis 
using amphotericin B deoxycholate at the Kenyatta 
National Hospital despite efforts aimed at prevention 
and correction. 
 The limitations of the study included the fact 
that hypokalaemia and hypomagnesaemia could have 
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been confounded by other factors such as poor feeding 
and vomiting. Although this study’s exclusion criteria 
took care of the previously studied nephrotoxic drugs, 
it did not eliminate the other co-administered drugs 
that may still be nephrotoxic albeit slightly. 
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